Glenmark Pharmaceuticals Inc., USA is charged with knowingly entering into and engaging in a conspiracy to suppress and eliminate competition by agreeing to increase and maintain prices of pravastatin and other generic drugs sold in the United States. The charged conspiracy began at least as early as May 2013 and continued at least until December 2015.
For further information:
For questions about upcoming public hearings or victims’ rights, contact the Victim Hearing Coordinator in the Washington Criminal II Section.
Superseding Indictment (July 14, 2020)
Information (June 30, 2020)